Arvidsson Rådestig, Maya
Skoog, Ingmar
Skillbäck, Tobias
Zetterberg, Henrik
Kern, Jürgen
Zettergren, Anna
Andreasson, Ulf
Wetterberg, Hanna
Kern, Silke
Blennow, Kaj
Funding for this research was provided by:
University of Gothenburg
Article History
Received: 22 December 2022
Accepted: 14 February 2023
First Online: 3 March 2023
Declarations
:
: All participants and/or their close relatives gave written informed consent to participate in the study. The study was approved by the Regional Ethical Review Board in Gothenburg (Approval number 869-13) and was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: SK has served at scientific advisory boards and /or as consultant for Biogen and Geras Solutions (outside the work of this paper). HZ has served at scientific advisory boards and / or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophics, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare no competing interests.